About: EAACI position statement on asthma exacerbations and severe asthma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: EAACI position statement on asthma exacerbations and severe asthma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	EAACI position statement on asthma exacerbations and severe asthma
Creator	Pavord, I Sl, Johnston Johnston, S Demoly, P Hamelmann, E Ca, Akdis Akdis, C Bel, E Martinez, F Giacco, S Custovic, A Eh, Bel Fabbri, L Gaga, M Giacco, Del Holloway, J Jw, Holloway Kalayci, O Le Sou€ Ef, P L€ Otvall, J Magnan, A M€ Akel€ A 13, M O'byrne, P O'byrne, Saglani Papadopoulos, & Papi, A Ryan, D Saglani, S Sergejeva, S Sou€ Ef P, Le
Source	Medline; PMC
abstract	Asthma exacerbations and severe asthma are linked with high morbidity, significant mortality and high treatment costs. Recurrent asthma exacerbations cause a decline in lung function and, in childhood, are linked to development of persistent asthma. This position paper, from the European Academy of Allergy and Clinical Immunology, highlights the shortcomings of current treatment guidelines for patients suffering from frequent asthma exacerbations and those with difficult‐to‐treat asthma and severe treatment‐resistant asthma. It reviews current evidence that supports a call for increased awareness of (i) the seriousness of asthma exacerbations and (ii) the need for novel treatment strategies in specific forms of severe treatment‐resistant asthma. There is strong evidence linking asthma exacerbations with viral airway infection and underlying deficiencies in innate immunity and evidence of a synergism between viral infection and allergic mechanisms in increasing risk of exacerbations. Nonadherence to prescribed medication has been identified as a common clinical problem amongst adults and children with difficult‐to‐control asthma. Appropriate diagnosis, assessment of adherence and other potentially modifiable factors (such as passive or active smoking, ongoing allergen exposure, psychosocial factors) have to be a priority in clinical assessment of all patients with difficult‐to‐control asthma. Further studies with improved designs and new diagnostic tools are needed to properly characterize (i) the pathophysiology and risk of asthma exacerbations, and (ii) the clinical and pathophysiological heterogeneity of severe asthma.
has issue date	2013-11-06(xsd:dateTime)
bibo:doi	10.1111/all.12275
bibo:pmid	24410781
has license	no-cc
sha1sum (hex)	4e556003931c442a57e976bf98f661cc3f73178a
schema:url	https://doi.org/10.1111/all.12275
resource representing a document's title	EAACI position statement on asthma exacerbations and severe asthma
has PubMed Central identifier	PMC7159478
has PubMed identifier	24410781
schema:publication	Allergy
resource representing a document's body	covid:4e556003931c442a57e976bf98f661cc3f73178a#body_text
is schema:about of	named entity 'asthma' named entity 'EAACI' named entity 'EAACI' named entity 'Allergy' named entity 'severe' named entity 'probability' named entity 'eosinophilic' named entity 'asthma' named entity 'atopy' named entity 'atopy' named entity 'asthma' named entity 'antiviral' named entity 'sputum' named entity 'atopy' named entity 'obesity' named entity 'angiogenesis' named entity 'biomarkers' named entity 'animal models' named entity 'Case-control studies' named entity 'asthma' named entity 'longitudinal data' named entity 'eosinophils' named entity 'asthma' named entity 'fungi' named entity 'asthma' named entity 'lung function' named entity 'pathophysiological' named entity 'clinical practice' named entity 'asthma' named entity 'epidemiological studies' named entity 'biomarkers' named entity 'Bayesian inference' named entity 'eczema' named entity 'serum' named entity 'Atopic' named entity 'inflammation' named entity 'asthmatic' named entity 'clinical phenotypes' named entity 'rhinovirus' named entity 'short-term' named entity 'emergency treatment' named entity 'pathophysiological' named entity 'allergens' named entity 'refractory' named entity 'asthma exacerbations' named entity 'asthma' named entity 'eosinophil' named entity 'asthma' named entity 'primary care' named entity 'asthma' named entity 'coronavirus' named entity 'lung function'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software